



β -blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications

Stefano Taddei, Nqoba Tsabedze & Ru-San Tan

To cite this article: Stefano Taddei, Nqoba Tsabedze & Ru-San Tan (2024) β -blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications, Current Medical Research and Opinion, 40:sup1, 15-23, DOI: 10.1080/03007995.2024.2318058

To link to this article: <https://doi.org/10.1080/03007995.2024.2318058>



© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group



Published online: 10 Apr 2024.



Submit your article to this journal [↗](#)



View related articles [↗](#)



View Crossmark data [↗](#)

REVIEW ARTICLE



β -blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications

Stefano Taddei^a , Nqoba Tsabedze^b  and Ru-San Tan^{c,d} 

^aClinical and Experimental Medicine, University of Pisa, Pisa, Italy; ^bDivision of Cardiology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ^cDepartment of Cardiology, National Heart Centre Singapore, Singapore; ^dCardiovascular Sciences, Duke NUS Medical School, Singapore

ABSTRACT

β -blockers are a heterogeneous class, with individual agents distinguished by selectivity for β_1 - vs. β_2 - and α -adrenoceptors, presence or absence of partial agonist activity at one of more β -receptor subtype, presence or absence of additional vasodilatory properties, and lipophilicity, which determines the ease of entry the drug into the central nervous system. Cardiosensitivity (β_1 -adrenoceptor selectivity) helps to reduce the potential for adverse effects mediated by blockade of β_2 -adrenoceptors outside the myocardium, such as cold extremities, erectile dysfunction, or exacerbation of asthma or chronic obstructive pulmonary disease. According to recently updated guidelines from the European Society of Hypertension, β -blockers are included within the five major drug classes recommended as the basis of antihypertensive treatment strategies. Adding a β -blocker to another agent with a complementary mechanism may provide a rational antihypertensive combination that minimizes the adverse impact of induced sympathetic overactivity for optimal blood pressure-lowering efficacy and clinical outcomes benefit.

ARTICLE HISTORY

Received 20 November 2023
Revised 31 January 2024
Accepted 7 February 2024

KEYWORDS

β -blockade; bisoprolol; hypertension; heart failure; combination therapy

Introduction

The clinical use of β -adrenergic receptor antagonists (β -blockers) began nearly 60 years ago with the invention of propranolol by Black et al.¹ The initial therapeutic use was for angina pectoris, but soon extended to managing hypertension and other cardiovascular disorders². Propranolol is a non-selective β -blocker that blocks β -adrenoceptors indiscriminately. Following its introduction, different subtypes of β -adrenergic receptors were discovered in the heart, vasculature and elsewhere; and research to develop specific receptor subtype blockers grew apace, along with elucidation of variations in their molecular pharmacology and the clinical applications².

Currently available β -blockers are a heterogeneous class of therapeutic agents and significant intra-class differences in individual drug selectivity, lipophilicity, and potential for partial agonism can inform the choice of β -blocker for a patient with one or more of a range of comorbid conditions³. This article reviews the clinical pharmacology of β -blockers, with an emphasis on the difference between members of this heterogeneous class. With regard to hypertension treatment, the use of guideline-recommended combinations of two or more antihypertensive agents has been reviewed in an accompanying article and we will also consider the relevance of variations in β -blocker pharmacology for their use within combination regimens. Other accompanying articles in this series explore the implications of the properties of individual

β -blockers for tolerability and safety⁴, and the management of hypertension⁵, coronary heart disease⁶, and heart failure⁷.

β -adrenergic receptors: where they are and what they do

Table 1 provides an overview of the actions of β_1 -, β_2 - and β_3 -adrenoceptors in the heart, vascular smooth muscle, the bronchial airways and the kidney^{8–15}. More detail on the function of each β -receptor subtype is given below. However, this section focuses mainly on those tissues most relevant to the efficacy and tolerability of β -blockers.

The β_1 -adrenoceptor is expressed mainly in the heart, kidney and adipocytes. Activation of cardiac β_1 -adrenoceptors, mainly by noradrenaline released by sympathetic nerves or adrenaline from the adrenal cortex, activates adenylate cyclase, inducing an increase in cyclic adenosine monophosphate in cardiac myocytes. This, in turn, promotes the influx of extracellular calcium into cardiomyocytes, resulting in increases in contractility (and oxygen consumption) and heart rate (via increases in conduction velocities in the sinus node pacemaker and atrioventricular nodal tissues). The intensity of β_1 -adrenoceptor stimulation is regulated by the balance between the sympathetic and parasympathetic nervous systems, modulated by baroreceptors located in the carotid sinus¹⁶. A sudden increase in autonomic and hormonal cardiac β_1 -adrenoceptor stimulation constitutes an important part of the “fight or flight” reflex, where additional

CONTACT Stefano Taddei  stefano.taddei@med.unipi.it  University of Pisa, Pisa, Italy

© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
www.cmjournal.com

Table 1. Overview of key actions of β_1 - and β_2 -adrenoceptors.

	β_1 -adrenoceptors	β_2 -adrenoceptors	β_3 -adrenoceptors
Myocardium	↑ Contractility and heart rate ↑ Myocardial necrosis/apoptosis	↓ Myocardial necrosis/apoptosis	Variable effects on contractility ⁹ Limited evidence for positive chronotropy
Bronchial smooth muscle	–	↑ Bronchodilation	↑ Bronchodilation (varies with species, uncertain in humans)
Vascular smooth muscle	–	↑ Vasodilatation	↑ Vasodilatation
Kidney	↑ Renin release	Possible nephroprotective effect	↑ Activity of water-solute transporters
Adipocytes	↑ Lipolysis	↑ Lipolysis	↑ Lipolysis

Notes: Possible decrease in contractility mediated *via* a nitric oxide-related mechanism, or increase in contractility associated with increased intracellular cAMP production. Compiled from information presented in references^{8–15}.

blood flow to muscles from enhanced cardiac performance contributes to heightened ability to escape from an imminent threat¹⁷. The density of β_1 -adrenoceptors in the heart outnumbers that of β_2 -adrenoceptors (see below) by about 4:1, although this ratio may reduce to as low as 1:1 in the setting of HFrEF or certain other cardiovascular diseases¹¹.

The β_2 -adrenoceptor is expressed mainly in the vasculature and smooth muscles of the airways, as well as, to some extent, in the heart and a range of other cell types. Activation of β_2 -adrenoceptors causes relaxation of smooth muscles through cyclic adenosine monophosphate-dependent mechanisms that involve activation of protein kinase A with reduction of calcium influx, sequestration and storage of intracellular calcium (in contrast to β_1 -adrenoceptor effects in cardiomyocytes, as described above)¹¹. Accordingly, stimulation of β_2 -adrenoceptors may cause vasodilatation, reduction of blood pressure (BP) and reflex tachycardia. Activation of β_2 -adrenoceptors also increases energy expenditure and improves glucose homeostasis¹⁸. On the other hand, blockade of β_2 -adrenoceptors causes vasoconstriction (with reduced blood flow to the extremities), bronchoconstriction and disturbances of metabolic function^{19,20}. Adrenaline activates β_2 -adrenoceptors more effectively than noradrenaline and is the main contributor to β_2 -adrenoceptor tone under physiological conditions.

The β_3 -adrenoceptor is a relatively new addition to the knowledge base of β -adrenergic function, having been cloned in 1989. Activation of β_3 -adrenoceptors increases the production of nitric oxide, which reduces cardiac contractility and induces vasodilatation in the peripheral arteries; these actions may oppose overactivation of either β_1 - or β_2 -adrenoceptors, which are potentially cardioprotective mechanisms^{14,15,19}. Interestingly, the expression of β_3 -adrenoceptors is increased in the failing heart²¹, and experimental evidence suggest that upregulation of β_3 -adrenoceptors in the heart in the setting of chronic heart failure may promote positive inotropism²². In addition, they are able to activate brown adipose tissue as well as inducing browning of white adipose tissue, with associated increased thermogenesis and energy expenditure²³. Consequently, research interest in the potential of β_3 -adrenoceptor agonists as anti-obesity agents has burgeoned.

Pharmacologic properties of individual β -blockers

Administration and pharmacokinetics

Posology, administration and elimination

Table 3 summarizes key aspects of administration, pharmacokinetics and elimination of commonly used β -blockers,

including β_1 -adrenoceptor selective agents (bisoprolol, metoprolol and atenolol), agents with additional vasodilatory properties (nebivolol, carvedilol), and the prototype non-selective β -blocker, propranolol, based on information contained in labelling and hypertension management guidelines from three large regions of the world (Europe, the USA and China)^{24–27}. The long plasma half-life of bisoprolol allows for once-daily dosing; pharmacodynamic studies confirm its effective β -blockade throughout the 24-h dosing interval²⁸. In contrast, a randomized study in patients with angina pectoris found that reductions in maximal heart rate and the double-product of heart rate and BP were more attenuated with atenolol versus nadolol, implying a less than 24-h true duration of action of atenolol²⁹. The elimination half-lives of metoprolol, carvedilol and propranolol are all shorter than that of bisoprolol. Nebivolol is metabolized by hepatic cytochrome CYP2D6 enzymes, and is sensitive to genetic polymorphisms that are expressed as “fast/extensive” or “slow/poor” metabolizer phenotypes. Accordingly, the bioavailability and plasma levels of nebivolol can exhibit substantial individual variations³⁰. The presence of active metabolites also complicates the pharmacokinetics of nebivolol, carvedilol and propranolol.

Bisoprolol undergoes almost complete absorption *via* the gut, and its balanced renal and hepatic elimination routes limit the impact of functional organ impairment on drug exposure^{31,32}. This contrasts with other β -blockers that are either eliminated mainly by the kidney (atenolol) or liver (metoprolol, nebivolol, carvedilol, propranolol), for which dose reductions become obligatory in the setting of significant dysfunction of these organ systems. Finally, while there is little first-pass metabolism with bisoprolol, the extensive hepatic metabolism or excretion of metoprolol, nebivolol, carvedilol and propranolol reduce their bioavailability substantially.

Inter-individual variation in pharmacokinetics

The complexity of the pharmacokinetic profiles of individual β -blocker drugs (Table 2) is directly related to the predilection for inter-individual variability in drug exposure, which has been quantified in a systematic review³³. Figure 1 shows the proportions of studies with β -blockers that demonstrated high variability in the respective areas under the drug concentration-time curve (a standard measure of drug exposure); high variability being defined as a coefficient of variation that exceeds 40%. Focusing on the β -blockers listed in Table 3, pharmacokinetic variability was substantial for all β -blockers, with the exception of bisoprolol and atenolol.

Drug-drug interactions

β -blockers, in general, are susceptible to important drug-drug interactions. For example, drug concentrations may increase leading to excessive reductions in heart rate and/or myocardial contractility when β -blockers are used in combination with non-dihydropyridine calcium channel blockers (CCB), centrally-acting antihypertensive agents, or amiodarone, which may produce adverse events in patients with pre-existing myocardial dysfunction³⁴. Combination with a dihydropyridine CCB or non-steroidal anti-inflammatory enhances the hypotensive effect, which may be the intended effect when prescribing β -blocker-CCB combination antihypertensive therapy²⁶. Drug-drug interactions for individual β -blockers depend largely on their metabolism. For example,

Table 2. Subclasses of β -blockers.

		β_1 receptor antagonist selectivity?	
Intrinsic sympathomimetic activity?		Yes	No
		Bisoprolol Metoprolol Atenolol Esmolol Xamoterol Acebutolol ^b Celiprolol ^{a,b} Nebivolol ^c	Propranolol Sotalol Timolol Carvedilol ^a Pindolol ^b Oxprenolol Labetolol ^a Bucindolol ^a

Notes: Additional vasodilation: ^ablocks α -adrenoceptors; ^bstimulates β_2 -adrenoceptors; ^cactivates β_3 -adrenoceptors. Reproduced from reference³¹ according to Creative Commons Attribution – Non Commercial v3.0 Licence (<http://creativecommons.org/licenses/by-nc/3.0/>).

Table 3. Administration, key pharmacokinetic parameters and administration of some commonly used β -blockers.

Drug	Posology	Plasma half-life (h)	Bioavailability	Absorption from the GI tract	Elimination	Active metabolites?
Bisoprolol ^a			90%	Almost complete	Evenly <i>via</i> renal excretion and hepatic metabolism	No
Europe	5–20 mg QD	10–12				
China	2.5–10 mg QD	10–12				
USA	5–20 mg QD	9–12				
Metoprolol ^a			50%	Complete	Primarily <i>via</i> hepatic CYP2D6	No
Europe	50–200 mg QD ^d	1–9 ^e				
China	50–100 mg QD	3–4				
USA	25–200 mg QD	3–7				
Atenolol ^a			About 50%	About 50%	Primarily <i>via</i> the kidney	No
Europe	50–100 mg QD	6–10				
China	12.5–50 mg BID	6–10				
USA	50–100 mg QD	6–7				
Nebivolol ^{a,b}			12–100% ^e	Complete	Extensive hepatic metabolism ^f	Yes
Europe	2.5–5 mg QD	10–50 ^f				
China	5 mg QD	12–19				
USA	5–40 mg QD	12–19				
Carvedilol ^c			25%	Complete	Mainly <i>via</i> bile and faeces	Yes
Europe	12.5–50 mg BID ^f	6				
China	12.5–50 mg BID	6–7				
USA	6.25–25 mg BID	7–10				
Propranolol			25%	Complete	Primarily <i>via</i> hepatic metabolism	Yes
Europe	80–160 mg BID	2				
China	20–90 mg BID	2–3				
USA	40–120 mg BID ^g	3–6				

^aSelective for β_1 -adrenoceptors.

^bAlso stimulated production of nitric oxide.

^cAlso blocks α_1 -adrenoceptors.

^dDose must not exceed 400 mg.

^eAverage 3.5 h.

^fAccording to a “fast metabolizer” or “slow metabolizer” phenotype arising from genetic variation in the hepatic cytochrome CYP2D6 system. BID administration is recommended for patients with angina pectoris.

^gDose can be as high as 640 mg/day if required. Administration: BID = twice-daily; QD = once daily. Values for half life and bioavailability are approximate. Abstracted from information provided in European Summaries of Product Characteristics (www.medicines.org.uk), US Prescribing Information (www.fdaaccess-data.gov) and references^{24,25}. Recommended dosages may vary between those shown here and documents from other regulatory authorities or expert societies or between different formulations of the same drugs.

combination of metoprolol or nebivolol with another agent extensively eliminated *via* the hepatic CYP2D6 pathway is likely to increase exposure to both drugs. Non-selective β -blockers increase blood glucose and are thus likely to oppose the effect of antihyperglycaemic medications, while highly β_1 -adrenoceptor selective agents are much less likely to do so³¹.




Figure 1. Variability of exposure to different β -blockers from a systematic review of pharmacokinetic studies. Information in parentheses next to drug names is (number of studies involving single dose [SS] administration/number of studies involving multiple dose [MD] administration to pharmacokinetic steady state). AUC, area under the plasma concentration-time curve. Note that the 100% values for nebivolol and carvedilol are based on a single available study. Drawn from data presented in reference³³.

Properties influencing interactions with adrenoceptors

Receptor selectivity

Table 2 summarizes the receptor selectivity of common β -blockers used in clinical practice³¹. Propranolol, sotalol, timolol, carvedilol, pindolol, oxprenolol, labetalol, and bucindolol block both β_1 - and β_2 -adrenoceptors. In contrast, bisoprolol, metoprolol, atenolol, xamoterol, acebutolol, celiprolol, nebivolol and esmolol (an agent with ultra-short duration of action that is used exclusively in specialized care settings) are cardioselective for the β_1 - vs. β_2 -adrenoceptor. Among the latter, the level of β_1 -adrenoceptor selectivity in individual agents differs. In an experiment that used cloned human β -adrenoceptors to measure the β_1 - vs. β_2 -adrenoceptor selectivity of different β -blockers³⁵, bisoprolol and xamoterol were shown to be the most selective for β_1 -adrenoceptors (14-fold selective), followed by atenolol (4.7-fold selective), acebutolol (2.4-fold selective), and metoprolol (2.3-fold selective). In another study that assessed the clinical pharmacodynamic effects of various β -blockers on terbutaline (a selective β_2 -adrenoceptor agonist)-induced tachycardia, nebivolol and bisoprolol were found to be more β_1 -selective than atenolol, especially when the higher dose of atenolol (100 mg) was used³⁶. The higher recommended dose of atenolol (100 mg) has been described as blocking about 25% of β_2 -adrenoceptors, compared with effectively zero for the higher recommended dose of bisoprolol (10 mg)³⁰. Comparisons of β_1 -selectivity between bisoprolol and nebivolol have been mixed, showing higher β_1 -selectivity for nebivolol in studies on human myocardium^{37,38}, but higher β_1 -selectivity for bisoprolol in a study that used cloned β -adrenoceptors³⁹.

A re-analysis of a published meta-analysis suggested that atenolol may be less effective than other β -blockers in reducing the risk of adverse cardiovascular outcomes in patients with hypertension, although the reasons for this finding remain unclear⁴⁰. A relatively high dose of carvedilol (non-cardioselective β -blocker with additional α_1 -adrenoceptor blockade) was found to confer mortality benefit versus a less potent dose of metoprolol (cardioselective β -blocker) in patients with HFrEF in the Carvedilol Or Metoprolol European Trial (COMET)⁴¹: this finding emphasizes the importance of considering equipotent dosages when comparing drugs with different β -adrenoceptor selectivity.

A recent study applied the concept of kinetic selectivity to investigate ways in which individual β -blockers interact with cloned β_1 - and β_2 -adrenoceptors expressed in cultured cells⁴². Among cardioselective β -blockers, the rate of association of bisoprolol with the β_1 -adrenoceptor was slower compared with either metoprolol or atenolol. However, bisoprolol's rate of dissociation was also much slower than either drug, resulting in a longer overall average time of occupation of the β_1 -adrenoceptor. Another part of this study involved incubating cells containing β_1 - or β_2 -adrenoceptors at concentrations of β -blockers that were 30-fold higher than their individual K_d values (the concentration at which half the target receptors become occupied). At this high relative concentration, all β_1 -adrenoceptors were effectively occupied by bisoprolol, metoprolol, atenolol or carvedilol; occupancy rates

of β_2 -adrenoceptors were 95–100% for all agents except for bisoprolol with about 55% occupancy. When the β -blockers were removed, bisoprolol dissociated completely from β_2 -adrenoceptors within seconds, compared with about 40 min for its dissociation from β_1 -adrenoceptors. Dissociation rates of metoprolol and atenolol from both β_1 - vs. β_2 -adrenoceptors were more similar, while carvedilol dissociated from β_1 -adrenoceptors more quickly than from β_2 -adrenoceptors. These experimental findings underpin the observed clinical differences in β receptor selectivity among individual members of the β -blocker class.

Blockade of β_2 -adrenoceptors accounts for important adverse effects of β -blockers, including bronchoconstriction, adverse effects on glycaemia and erectile dysfunction³¹. A highly β_1 -selective β -blocker such as bisoprolol has little or no effect on the peripheral vasculature at full β -blocking doses, unlike non-selective or less selective agents⁴³. Similarly, cardioselective β -blockade has little effect on airway smooth muscle (these drugs have no absolute contraindication in people with obstructive airways disease)⁴⁴, glucose metabolism^{45,46}, or erectile performance⁴⁷ (further details on these issues are available from an accompanying article in this series⁴). A placebo effect may apply to some reports of erectile dysfunction with β -blockers, likely due to patients being briefed to expect this side-effect⁴⁸. These observations are important, as there is evidence that β -blockers are underused in populations with airway diseases or diabetes, with patients denied the outcome benefits associated with the use of these drugs⁴⁹. Finally, reports of increased blood pressure variability with β -blockers vs. other antihypertensive classes may relate less to cardioselective or vasodilating β -blockers, compared with non-selective β -blockers^{50–53}. Most people with hypertension will receive antihypertensive combination therapy^{26,27} (see below) and reductions in blood pressure variability induced by calcium channel blockers persist when other antihypertensive agents are added⁵².

Lipophilicity

β -blockers differ considerably in their physical chemistry. Lipophilic (oil-soluble) β -blockers are more likely than hydrophilic (water-soluble) β -blockers to enter the central nervous system (CNS) and exert their pharmacological actions there. Pindolol, timolol and propranolol are highly lipophilic; nadolol, atenolol and labetalol are highly hydrophilic; and metoprolol, bisoprolol, nebivolol, acebutolol and carvedilol exhibit moderate lipophilicity/hydrophilicity⁵⁴. Treatment with β -blockers has been reported to induce neuropsychiatric side-effects in some patients, raising the hypothesis that the degree of lipophilicity of a β -blocker might be predictive of the risk of CNS side-effects⁵⁴. However, this hypothesis was refuted by a meta-analysis, which showed that the incidence of side-effects that were possibly related to drug actions in the CNS (depression, fatigue, sexual dysfunction) during treatment with a β -blocker was not related to the degree of lipophilicity of the drugs prescribed⁵⁵.

Inverse agonism

β -adrenoceptors, like many G-protein coupled receptors, maintain a low level of intracellular signal transduction without an agonist⁵⁶. An inverse agonist is a molecule that binds to the receptor and stabilizes it in such a way that the level of constitutive activity is reduced, compared with the unbound receptor, i.e. an inverse agonist has the opposite action to an agonist⁵⁷. Most ligands at both β_1 - and β_2 -adrenoceptors demonstrate at least some inverse agonism. This phenomenon reduces the rate of desensitization of receptors, and increases their density on the heart or vascular cell surface⁵⁷. Some differences in the inverse agonist activity of β -blockers have been described, with higher inverse activity for atenolol, metoprolol, nebivolol and bisoprolol than for carvedilol³⁹. However, evidence for a true clinical benefit associated with the presence or absence of inverse agonism at the β_1 -adrenoceptor is lacking, and other aspects of β -blocker pharmacology are likely to exercise more importance in defining the therapeutic and clinical profiles of these agents.

Biased signal transduction

Classical receptor theory dictates that a receptor exists in one of two fundamental states: quiescent (inactive) or stimulated (active). Biased signal transduction refers to the observation that two ligands at the same receptor can activate different intracellular transduction pathways⁵⁸. In the case of β_2 -adrenoceptors, differential activation by different drugs of the classical G-protein coupled signal cascade and the β -arrestin pathway has instigated much research in recent years⁵⁸. For example, carvedilol acts at the β_2 -adrenoceptor as an inverse agonist at the classical G-protein-coupled signal transduction pathway and as a partial agonist at the β -arrestin pathway^{59,60}. Nebivolol, usually described as a β_1 -adrenoceptor antagonist with additional vasodilator properties, also partially activates the β -arrestin pathway downstream of the β_2 -adrenoceptor^{59,60}. Biased signal transduction at β -adrenoceptors has also been described for cardioselective β -blockers, including bisoprolol⁶¹ and metoprolol⁶².

Variations in the level of biased signal transduction have been cited as an important source of the broad pharmacologic heterogeneity of this class^{59,60}. While the impact of the activation of β -arrestins on downstream signalling from G-protein coupled receptors is complex and pleiotropic, potential benefits from exploiting this pathway have been proposed for cardiovascular and numerous other fields of medicine⁵⁸. Further research will be required to translate this potential into proven clinical benefit.

Other sympathoinhibitory mechanisms

β -blockers reduce the activity of the sympathetic nervous system by inhibiting presynaptic β_1 -adrenoceptors and thus reducing the release of adrenaline and noradrenaline (epinephrine and norepinephrine), in addition to interacting with postsynaptic β -adrenoceptors in the heart, vasculature and elsewhere⁶³. Other mechanisms are at play, however, which vary between individual agents and contribute to the

heterogeneity of the β -blocker class^{63,64}. For example, non-lipophilic β -blockers are unable to enter the brain and reduce sympathetic nerve traffic there (see the section on lipophilicity, above). Effects of β -blockers on baroreflex function also vary⁶³. Polymorphisms in β_1 -adrenoceptors can also modulate the clinical response to β -blocker treatment in heart failure⁶⁴. Finally, a study in humans with heart failure treated with carvedilol or metoprolol demonstrated lower levels of coronary sinus noradrenaline (a marker of the intensity of cardiac sympathetic innervation) and density of β_1 -adrenoceptors on the myocardium with carvedilol⁶⁵.

Dialyzability

Patients on haemodialysis have been largely excluded from clinical trials, despite as many as 80% of this population having comorbid hypertension⁶⁶. One study found that 64% of the United States Medicare population receiving dialysis for end-stage renal dysfunction were receiving a β -blocker⁶⁷. Among β -blockers, atenolol and metoprolol are highly dialysable, i.e. cleared effectively from the circulation by dialysis; bisoprolol is moderately dialysable; and carvedilol, nebivolol and propranolol exposure are little affected by dialysis⁶⁸.

β -blockers and peripheral vasodilatation

Intrinsic sympathomimetic activity (ISA) at the β_1 -adrenoceptor

Some β -blockers demonstrate ISA, acting as partial agonists at the β_1 - or β_2 -adrenoceptor (Table 2). Non-selective β -blockers with ISA may activate β_2 -adrenoceptors and induce peripheral vasodilatation⁶⁹. For cardioselective β -blockers with ISA, the pharmacodynamic reductions of heart rate and contractility may be attenuated, compared with those without ISA; for non-selective β -blockers, ISA may limit the potential for adverse effects or coldness of the extremities⁵⁰. However, there is no compelling evidence that ISA directed at the β_1 -adrenoceptor confers any clinical outcome benefit; in fact, the opposite may be true: in a meta-analysis, the presence of ISA reduced the clinical benefit of β -blockers in patients with stable CHD⁷⁰. In a placebo-controlled study, xamoterol (a β -blocker with pronounced β_1 -adrenoceptor-directed ISA) induced modest improvements in dyspnoea severity, with minimal effects on other symptoms, in patients with severe symptomatic HFrEF (New York Heart Association [NYHA] class III–IV)⁷¹. Importantly, patients randomized to xamoterol had a more than two-fold higher mortality rate within 100 days of randomization compared with the control group (9.1% vs. 3.7%, $p = .02$). Another randomized trial demonstrated no survival benefit for bucindolol (another β -blocker with ISA directed at the β_1 -adrenoceptor) versus placebo in patients with NYHA III–IV HFrEF⁷². β -blockers without ISA improve outcomes in heart failure³¹; indeed, expert opinion suggests that the absence of ISA is a key pre-requisite for optimal clinical outcomes with β -blocker therapy⁸.

Additional vasodilatory mechanisms of action

Peripheral vasodilation can also be induced by upregulated nitric oxide production, e.g. due to stimulation of β_3 -

adrenoceptors by nebivolol⁷³. BP reduction may ensue in either case. Any resultant reflex tachycardia is likely to be counterbalanced by the effects of β_1 -adrenoceptor blockade, which minimizes changes in the heart rate compared with a cardioselective agent. However, there is no clear evidence that partial agonism to β_2 - or β_3 -adrenoceptor confers additional outcomes benefit over a cardioselective β -blocker. Bisoprolol, a highly cardioselective β_1 -blocker without ISA, exhibited equal BP-lowering efficacy vs. nebivolol, a highly cardioselective β_1 -blocker with β_3 -adrenoceptor agonism, both drugs in a small single-blind trial⁷⁴. While head-to-head randomized outcomes trials between agents with and without vasodilatory properties are lacking, the clinical outcomes of bisoprolol versus nebivolol were reported to be similar for management of patients with heart failure in a meta-analysis⁷⁵, and of patients with cardiovascular diseases in a review⁷⁶. No significant differences in clinical outcomes were demonstrated between propensity score-matched patients with hypertension treated with first- versus third-generation β -blockers (with and without additional vasodilatory activity, respectively) in a large observational study⁷⁷. Lastly, carvedilol, labetalol, celiprolol and bucindolol all block α_1 -adrenoceptors, which constitutes an additional mechanism that can induce peripheral vasodilation⁷⁸. Of note, carvedilol can effectively reduce heart rate despite the potential for vasodilatation-associated reflex tachycardia⁷⁹. These observations may be important clinically, as reduction of heart rate has been proposed as a mechanism leading to improved outcomes in patients with heart failure⁸⁰.

Implications for β -blocker-based combination therapy

The recently published (2023) European Society of Hypertension (ESH) clinical practice guideline for diagnosing and managing hypertension includes β -blockers within the five main classes of antihypertensive agents suitable for first-line use²⁶. This is largely due to recognizing that risk reduction of adverse cardiovascular events is dependent on the magnitude of BP lowering *per se*, rather than the pharmacologic properties of the different antihypertensive drug classes. As stroke outcomes appear especially sensitive to central BP, the slightly lower efficacy of β -blockade for reducing central BP compared with other drug classes, particularly CCBs, may attenuate its efficacy for lowering stroke risk²⁶. However, as most patients with hypertension require combinations of antihypertensive drugs for adequate BP control, the reduced efficacy of β -blockers for central BP lowering need not be a critical limitation. While a combination of an angiotensin converting enzyme inhibitor and CCB is often the first-choice combination treatment⁸¹, selective β -blockade may also fit well mechanistically into rational antihypertensive combinations for selected patients, especially those with established CHD or HFrEF. For example, adding a cardioselective β -blocker to a dihydropyridine CCB, which markedly reduces central blood pressure, will provide complementary and additional peripheral blood pressure lowering *via* β_1 -adrenoreceptor blockade in the heart^{82,83}. Of

note, CCBs may also increase the availability of nitric oxide in the vasculature⁸⁴ or block α_1 -adrenoceptors, both of which would enhance lowering of central blood pressures.

Activation of the sympathetic nervous system increases the activity of the renin-angiotensin-aldosterone system (RAAS), which in turn promotes sympathetic overactivity in a vicious circle, driving the development of hypertensive target organ disease and heart failure⁸⁵. Combining a cardioselective β -blockade with a RAAS blocker (an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker) thus represents a rational strategy for managing hypertension and other cardiovascular diseases. Importantly, β -blockers are as effective as other antihypertensive classes in reducing BP when added to an existing antihypertensive monotherapy⁸⁶. RAAS activation also reduces the response to a diuretic in patients with hypertension or HFrEF, providing further rationale for the efficacy of a β -blocker-diuretic combination in this setting⁸⁷. Finally, delivering antihypertensive combination therapy *via* fixed-dose single-pill combinations helps maintain treatment adherence, which is important for optimal BP goal attainment^{88,89}.

Current guidelines for managing heart failure recommend using β -blockers (principally bisoprolol, metoprolol, or carvedilol) for patients with HFrEF⁹⁰, although up to almost 90% of the populations of recent randomized trials in populations with HFpEF have received a β -blocker as background therapy⁹¹. Thus, cardiologists who have taken care of patients in randomized trials in populations with HFpEF found that β -blockers were indicated in the majority of the patients for reasons such as tachycardia (including rapid atrial fibrillation) and ischaemia due to left ventricular hypertrophy and/or macrovascular coronary disease. In the management of HFrEF, β -blockers are recommended to be combined with other pillars of therapy that may also have antihypertensive effects, including RAAS blockers or angiotensin receptor-neprilysin inhibitor, mineralocorticoid antagonist and sodium/glucose cotransporter-2 inhibitors⁹⁰. Recent research shows that the benefit of the relatively new class of sodium-glucose co-transporter 2 inhibitors is not diminished by continuing treatment with these other evidence-based background therapies⁹².

Conclusions

The updated ESH guidelines have restored β -blockade as one of the five main classes of antihypertensive therapy suitable for initiating pharmacologic antihypertensive therapy, especially in patients with cardiovascular comorbidities such as CHD or heart failure. In this review, we have set out to reinterpret the properties of this diverse therapeutic class in the light of the new evidence that has prompted this change in guidance. Recent management guidelines in this area have also emphasized the need to prescribe combination antihypertensive therapies for most people with hypertension. The mechanism of β -blockade is complementary to most other antihypertensive agents and adding a β -blocker to another agent with a complementary mechanism may provide a rational antihypertensive combination that reduces

the adverse impact of the activated RAAS on the cardiovascular system. Cardioselective β_1 -adrenoceptor β -blockers are as effective as other subclasses of β -blockers for BP management; and bisoprolol is one three cardioselective β -blockers (along with carvedilol) that are recommended for improving clinical outcomes in patients with HFrEF in current European guidance⁹⁰. Moreover, β_1 -selectivity helps to reduce the potential for adverse effects associated with the contraction of smooth muscle cells due to the blockade of β_2 -adrenoceptors, leading to cold extremities, erectile dysfunction, or exacerbation of asthma or chronic obstructive pulmonary disease³¹. At the same time, these agents remain strongly recommended for patients with defined cardiovascular comorbidities such as coronary heart disease or heart failure.

Transparency

Declaration of funding

Merck Healthcare KGaA, Darmstadt, Germany, funded open access publication of this collection of articles and editorial assistance. No other funding applied.

Declaration of financial/other relationships

ST has received research contracts from Boehringer Ingelheim, Idorsia, Novartis, AstraZeneca and speaker honoraria from Servier, Pfizer, Merck Serono, Sandoz, Neopharmed, Sharper, Medtronic. No conflict of interest is declared for writing this article. NT has received consulting & speaker fees from Acino Health Care Group, AstraZeneca, Boehringer-Ingelheim, Boston Scientific, Eli Lilly, Merck, Novartis Pharmaceuticals, NovoNordisk, Pfizer, Phillips, Sanofi, Servier and Takeda. NT has also received educational Grants from Biotronik, Boston Scientific, Medtronic, and Vertice Health Care Group. No conflict of interest is declared for writing this article. R-ST has received consulting & speaker fees from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, DiethelmKellerSiberHegner, Johnson & Johnson, Merck, Merck Sharp & Dohme, Novartis, NovoNordisk, and Pfizer. No conflict of interest is declared for writing this article. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

ST, NT, and R-ST contributed equally to the development of this article.

Acknowledgements

Dr Mike Gwilt (GT Communications) provided editorial assistance.

Supplement statement

This article is part of a supplement sponsored by Merck Healthcare KGaA, Darmstadt, Germany. All articles within this supplement have been rigorously peer reviewed by at least two experts in the field, as per CMRO's peer review policy. Any conflicts of interest are stated in the "Declaration of financial/other relationships" section.

Artificial intelligence (AI)

No AI-related technologies were used in the preparation of this article.

ORCID

Stefano Taddei  <http://orcid.org/0000-0002-5002-3070>

Nqoba Tsabedze  <http://orcid.org/0000-0002-7210-1447>

Ru-San Tan  <http://orcid.org/0000-0003-2086-6517>

References

- [1] Black JW, Crowther AF, Shanks RG, et al. A new adrenergic betareceptor antagonist. *Lancet*. 1964;1(7342):1080–1081. doi:[10.1016/S0140-6736\(64\)91275-9](https://doi.org/10.1016/S0140-6736(64)91275-9).
- [2] Srinivasan AV. Propranolol: a 50-year historical perspective. *Ann Indian Acad Neurol*. 2019;22(1):21–26. doi:[10.4103/aian.AIAN_201_18](https://doi.org/10.4103/aian.AIAN_201_18).
- [3] Mancía G, Kjeldsen SE, Kreutz R, et al. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. *Hypertension*. 2022; 79(6):1153–1166. doi:[10.1161/HYPERTENSIONAHA.122.19020](https://doi.org/10.1161/HYPERTENSIONAHA.122.19020).
- [4] Marti H-P, López AAP, Schwartzmann P. Safety and tolerability of β -blockers: importance of cardioselectivity. *Curr Med Res Opin*. 2024. doi:[10.1080/03007995.2024.2317433](https://doi.org/10.1080/03007995.2024.2317433).
- [5] Mahfoud F, Wang J, Ray S. The current position of β -blockers in hypertension: guidelines and clinical practice. *Curr Med Res Opin*. 2024. doi:[10.1080/03007995.2024.2318003](https://doi.org/10.1080/03007995.2024.2318003).
- [6] Palatini P, Faria-Neto JR, Santos RD. The clinical value of β -blockers in patients with stable angina. *Curr Med Res Opin*. 2024. doi:[10.1080/03007995.2024.2317443](https://doi.org/10.1080/03007995.2024.2317443).
- [7] de Oliveira MT Jr, Baptista R, Chavez-Leal SA, et al. Heart failure management with β -blockers: can we do better? *Curr Med Res Opin*. 2024. doi:[10.1080/03007995.2024.2318002](https://doi.org/10.1080/03007995.2024.2318002).
- [8] Cruickshank JM. Are we misunderstanding beta-blockers. *Int J Cardiol*. 2007;120(1):10–27. doi:[10.1016/j.ijcard.2007.01.069](https://doi.org/10.1016/j.ijcard.2007.01.069).
- [9] Egan BM, Basile J, Chilton RJ, et al. Cardioprotection: the role of beta-blocker therapy. *J Clin Hypertens (Greenwich)*. 2005;7(7): 409–416. doi:[10.1111/j.1524-6175.2005.04486.x](https://doi.org/10.1111/j.1524-6175.2005.04486.x).
- [10] Communal C, Singh K, Sawyer DB, et al. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. *Circulation*. 1999;100(22):2210–2212. doi:[10.1161/01.cir.100.22.2210](https://doi.org/10.1161/01.cir.100.22.2210).
- [11] Abosamak NR, Shahin MH. Beta 2 Receptor agonists/antagonists. *StatPearls* [Internet]; [accessed 2023 Oct]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559069/>
- [12] Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. *J Lipid Res*. 1993;34(7): 1057–1091. doi:[10.1016/S0022-2275\(20\)37695-1](https://doi.org/10.1016/S0022-2275(20)37695-1).
- [13] Alhayek S, Preuss CV. Beta 1 receptors. *StatPearls* [Internet]; [accessed 2023 Oct]. Available at <https://www.ncbi.nlm.nih.gov/books/NBK532904/>
- [14] Schena G, Caplan MJ. Everything you always wanted to know about β_3 -AR * (* but were afraid to ask. *Cells*. 2019;8(4):357. doi:[10.3390/cells8040357](https://doi.org/10.3390/cells8040357).
- [15] Arioglu-Inan E, Kayki-Mutlu G, Michel MC. Cardiac β_3 -adrenoceptors-a role in human pathophysiology? *Br J Pharmacol*. 2019; 176(14):2482–2495. doi:[10.1111/bph.14635](https://doi.org/10.1111/bph.14635).
- [16] Hasan W. Autonomic cardiac innervation: development and adult plasticity. *Organogenesis*. 2013;9(3):176–193. doi:[10.4161/org.24892](https://doi.org/10.4161/org.24892).
- [17] Goldstein DS. Adrenal responses to stress. *Cell Mol Neurobiol*. 2010;30(8):1433–1440. doi:[10.1007/s10571-010-9606-9](https://doi.org/10.1007/s10571-010-9606-9).
- [18] Hoeks J, van Baak MA, Hesselink MK, et al. Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. *Am J Physiol Endocrinol Metab*. 2003;285(4):E775–E782. doi:[10.1152/ajpendo.00175.2003](https://doi.org/10.1152/ajpendo.00175.2003).
- [19] Huang KY, Tseng PT, Wu YC, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. *Sci Rep*. 2021;11(1):452. doi:[10.1038/s41598-020-79837-3](https://doi.org/10.1038/s41598-020-79837-3).

- [20] Khouri C, Jouve T, Blaise S, et al. Peripheral vasoconstriction induced by β -adrenoceptor blockers: a systematic review and a network meta-analysis. *Br J Clin Pharmacol*. 2016;82(2):549–560. doi:10.1111/bcp.12980.
- [21] Michel LYM, Farah C, Balligand JL. The beta3 adrenergic receptor in healthy and pathological cardiovascular tissues. *Cells*. 2020; 9(12):2584. doi:10.3390/cells9122584.
- [22] Sabbah HN, Zhang K, Gupta RC, et al. Intravenous infusion of the β 3-adrenergic receptor antagonist APD418 improves left ventricular systolic function in dogs with systolic heart failure. *J Card Fail*. 2021;27(2):242–252. doi:10.1016/j.cardfail.2020.12.008.
- [23] Bhadada SV, Patel BM, Mehta AA, et al. β (3) receptors: role in cardiometabolic disorders. *Ther Adv Endocrinol Metab*. 2011;2(2):65–79. doi:10.1177/2042018810390259.
- [24] Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and treatment of hypertension—a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. *J Geriatr Cardiol*. 2019;16(3):182–241. doi:10.11909/j.issn.1671-5411.2019.03.014.
- [25] National Health and Family Planning Commission. Guidelines for rational medication use for hypertension (part 2). *Chin Med Front J (Electr Ed.)* (article in Chinese) 2017;9:28–126.
- [26] Mancia G, Kreutz R, Brunstrom M, et al. The task force for the management of arterial hypertension of the European Society of Hypertension. 2023 ESH guidelines for the management of arterial hypertension. Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). *J Hypertens* 2023;41:1874–2071.
- [27] Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2017;138:e484–e594.
- [28] Asmar R, Hugues C, Pannier B, et al. Duration of action of bisoprolol after cessation of a 4 week treatment and its influence on pulse wave velocity and aortic diameter: a pilot study in hypertensive patients. *Eur Heart J*. 1987;8 Suppl M:115–120. doi:10.1093/eurheartj/8.suppl_m.115.
- [29] Kostis JB. Comparison of the duration of action of atenolol and nadolol for treatment of angina pectoris. *Am J Cardiol*. 1988; 62(17):1171–1175. doi:10.1016/0002-9149(88)90254-8.
- [30] Briciu C, Neag M, Muntean D, et al. Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. *Clujul Med*. 2015;88(2):208–213. doi:10.15386/cjmed-395.
- [31] Pathak A, Mrabeti S. β -blockade for patients with hypertension, ischemic heart disease or heart failure: where are we now? *Vasc Health Risk Manag*. 2021;17:337–348. doi:10.2147/VHRM.S285907.
- [32] Brodde O-E. The pharmacology of bisoprolol. *Rev Contemp Pharmacother*. 1997;8:21–33.
- [33] Ågesen FN, Weeke PE, Tfelt-Hansen P, et al. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. *Pharmacol Res Perspect*. 2019;7(4):e00496. doi:10.1002/prp2.496.
- [34] Maideen NMP, Raj Kapoor B, Muthusamy S, et al. A review on pharmacokinetic and pharmacodynamic drug interactions of adrenergic β -blockers with clinically relevant drugs—an overview. *Curr Drug Metab*. 2021;22(9):672–682. doi:10.2174/1389200222666210614112529.
- [35] Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. *Br J Pharmacol*. 2005;144(3):317–322. doi:10.1038/sj.bjp.0706048.
- [36] Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. *J Clin Pharm Ther*. 2003;28(3):179–186. doi:10.1046/j.1365-2710.2003.00477.x.
- [37] Brixius K, Bundkirchen A, Böck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. *Br J Pharmacol*. 2001; 133(8):1330–1338. doi:10.1038/sj.bjp.0704188.
- [38] Bundkirchen A, Brixius K, Böck B, et al. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. *Eur J Pharmacol*. 2003;460(1):19–26. doi:10.1016/S0014-2999(02)02875-3.
- [39] Maack C, Tyroller S, Schnabel P, et al. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium. *Br J Pharmacol*. 2001;132(8):1817–1826. doi:10.1038/sj.bjp.0703992.
- [40] Aursnes I, Osnes JB, Tvete IF, et al. Does atenolol differ from other beta-adrenergic blockers? *BMC Clin Pharmacol*. 2007;7(1):4. doi:10.1186/1472-6904-7-4.
- [41] Bristow MR, Feldman AM, Adams KF Jr, et al. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? *J Card Fail*. 2003; 9(6):444–453. doi:10.1016/j.cardfail.2003.10.009.
- [42] Sykes DA, Jiménez-Rosés M, Reilly J, et al. Exploring the kinetic selectivity of drugs targeting the β 1 -adrenoceptor. *Pharmacol Res Perspect*. 2022;10(4):e00978. doi:10.1002/prp2.978.
- [43] Chang PC, van Veen S, van der Krogt JA, et al. Beta 1-adrenoceptor selectivity of single oral doses of bisoprolol and atenolol. *J Cardiovasc Pharmacol*. 1988;12(3):317–322. doi:10.1097/00005344-198809000-00009.
- [44] Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. *Respir Med*. 2011;105 Suppl 1: s44–S49. doi:10.1016/S0954-6111(11)70010-5.
- [45] Park Y, Choi BG, Rha SW, et al. Selective β 1-blockers are not associated with new-onset diabetes mellitus in hypertensive patients. *J Cardiovasc Pharmacol*. 2018;71(1):38–45. doi:10.1097/FJC.0000000000000543.
- [46] Owada A, Suda S, Hata T, et al. The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. *Clin Exp Hypertens*. 2001;23(4): 305–316. doi:10.1081/ceh-100102669.
- [47] Broekman CP, Haensel SM, Van de Ven LL, et al. Bisoprolol and hypertension: effects on sexual functioning in men. *J Sex Marital Ther*. 1992;18(4):325–331. doi:10.1080/00926239208412857.
- [48] Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. *Eur Heart J*. 2003;24(21):1928–1932. doi:10.1016/j.ehj.2003.08.016.
- [49] Lim KP, Loughrey S, Musk M, et al. Beta-blocker under-use in COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2017;12:3041–3046. doi:10.2147/COPD.S144333.
- [50] Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. *Am J Cardiol*. 1990;66(9):21C–23C. doi:10.1016/0002-9149(90)90758-s.
- [51] Webb AJ, Fischer U, Rothwell PM. Effects of β -blocker selectivity on blood pressure variability and stroke: a systematic review. *Neurology*. 2011;77(8):731–737. doi:10.1212/WNL.0b013e31822b007a.
- [52] Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. *Stroke*. 2011;42(10):2860–2865. doi:10.1161/STROKEAHA.110.611566.
- [53] Del Pinto R, Ferri C, Parati G. Reduction of blood pressure variability: an additional protective cardiovascular effect of vasodilating beta-blockers? *J Hypertens*. 2020;38(3):405–407. doi:10.1097/HJH.0000000000002334.
- [54] Cojocariu SA, Maștaleru A, Sascău RA, et al. Neuropsychiatric consequences of lipophilic beta-blockers. *Medicina*. 2021;57(2):155. doi:10.3390/medicina57020155.
- [55] Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. *JAMA*. 2002;288(3):351–357. doi:10.1001/jama.288.3.351.
- [56] Khilnani G, Khilnani AK. Inverse agonism and its therapeutic significance. *Indian J Pharmacol*. 2011;43(5):492–501. doi:10.4103/0253-7613.84947.
- [57] Michel MC, Michel-Reher MB, Hein P. A systematic review of inverse agonism at adrenoceptor subtypes. *Cells*. 2020;9(9):1923. doi:10.3390/cells9091923.

- [58] Bond RA, Lucero Garcia-Rojas EY, Hegde A, et al. Therapeutic potential of targeting β -arrestin. *Front Pharmacol*. 2019;10:124. doi:[10.3389/fphar.2019.00124](https://doi.org/10.3389/fphar.2019.00124).
- [59] Ippolito M, Benovic JL. Biased agonism at β -adrenergic receptors. *Cell Signal*. 2021;80:109905. doi:[10.1016/j.cellsig.2020.109905](https://doi.org/10.1016/j.cellsig.2020.109905).
- [60] Thanawala VJ, Forkuo GS, Stallaert W, et al. Ligand bias prevents class equality among beta-blockers. *Curr Opin Pharmacol*. 2014;16:50–57. doi:[10.1016/j.coph.2014.03.002](https://doi.org/10.1016/j.coph.2014.03.002).
- [61] Yang H, Du RZ, Qiu JP, et al. Bisoprolol reverses epinephrine-mediated inhibition of cell emigration through increases in the expression of β -arrestin 2 and CCR7 and PI3K phosphorylation, in dendritic cells loaded with cholesterol. *Thromb Res*. 2013;131(3):230–237. doi:[10.1016/j.thromres.2012.12.009](https://doi.org/10.1016/j.thromres.2012.12.009).
- [62] Nakaya M, Chikura S, Watari K, et al. Induction of cardiac fibrosis by β -blocker in G protein-independent and G protein-coupled receptor kinase 5/ β -arrestin2-dependent signaling pathways. *J Biol Chem*. 2012;287(42):35669–35677. doi:[10.1074/jbc.M112.357871](https://doi.org/10.1074/jbc.M112.357871).
- [63] Grassi G. Sympathomodulatory effects of antihypertensive drug treatment. *Am J Hypertens*. 2016;29(6):665–675. doi:[10.1093/ajh/hpw012](https://doi.org/10.1093/ajh/hpw012).
- [64] Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. *Circ Res*. 2013;113(6):739–753. doi:[10.1161/CIRCRESAHA.113.300308](https://doi.org/10.1161/CIRCRESAHA.113.300308).
- [65] Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. *Circulation*. 1996;94(11):2817–2825. doi:[10.1161/01.cir.94.11.2817](https://doi.org/10.1161/01.cir.94.11.2817).
- [66] Hundemer GL, Sood MM, Canney M. β -blockers in hemodialysis: simple questions, complicated answers. *Clin Kidney J*. 2020;14(3):731–734. doi:[10.1093/ckj/sfaa249](https://doi.org/10.1093/ckj/sfaa249).
- [67] Frankenfield DL, Weinhandl ED, Powers CA, et al. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare part D. *Am J Kidney Dis*. 2012;59(5):670–681. doi:[10.1053/j.ajkd.2011.10.047](https://doi.org/10.1053/j.ajkd.2011.10.047).
- [68] Weir MA, Dixon SN, Fleet JL, et al. B-blocker dialyzability and mortality in older patients receiving hemodialysis. *J Am Soc Nephrol*. 2015;26(4):987–996. doi:[10.1681/ASN.2014040324](https://doi.org/10.1681/ASN.2014040324).
- [69] Rosenthal J, Kaiser H, Raschig A, et al. Treatment of hypertension with a beta-adrenoceptor blocker. *Int J Clinical Practice*. 1979;33(6):165–181. doi:[10.1111/j.1742-1241.1979.tb07643.x](https://doi.org/10.1111/j.1742-1241.1979.tb07643.x).
- [70] Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ*. 1999;318(7200):1730–1737. doi:[10.1136/bmj.318.7200.1730](https://doi.org/10.1136/bmj.318.7200.1730).
- [71] The Xamoterol in Severe Heart Failure Study Group: xamoterol in severe heart failure. *Lancet*. 1990;336:1–6.
- [72] Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med*. 2001;344(22):1659–1667.
- [73] Cruickshank J. Expert opinion. Nebivolol, a third generation beta-blocker. *J Symptoms Signs*. 2014;5:380–390.
- [74] Czuriga I, Rieicansky I, Bodnar J, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). *Cardiovasc Drugs Ther*. 2003;17(3):257–263. doi:[10.1023/a:1026180325278](https://doi.org/10.1023/a:1026180325278).
- [75] Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. *BMJ*. 2013;346(jan16 1):f55. doi:[10.1136/bmj.f55](https://doi.org/10.1136/bmj.f55).
- [76] AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic properties of highly selective β -blockers with or without additional vasodilator properties: focus on bisoprolol and nebivolol in patients with cardiovascular disease. *Cardiovasc Drugs Ther*. 2022;36(5):959–971. doi:[10.1007/s10557-021-07205-y](https://doi.org/10.1007/s10557-021-07205-y).
- [77] Chan You S, Krumholz HM, Suchard MA, et al. Comprehensive comparative effectiveness and safety of first-line β -blocker monotherapy in hypertensive patients: a large-scale multicenter observational study. *Hypertension*. 2021;77(5):1528–1538. doi:[10.1161/HYPERTENSIONAHA.120.16402](https://doi.org/10.1161/HYPERTENSIONAHA.120.16402).
- [78] Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. *Eur Heart J*. 1996;17 Suppl B:8–16. doi:[10.1093/eurheartj/17.suppl_b.8](https://doi.org/10.1093/eurheartj/17.suppl_b.8).
- [79] Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. *Eur Heart J*. 2005;26(21):2259–2268. doi:[10.1093/eurheartj/ehi386](https://doi.org/10.1093/eurheartj/ehi386).
- [80] Cullington D, Goode KM, Clark AL, et al. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? *Eur J Heart Fail*. 2012;14(7):737–747. doi:[10.1093/eurjhf/hfs060](https://doi.org/10.1093/eurjhf/hfs060).
- [81] Taddei S. ACE-inhibitor/calcium antagonist combination: is this the first-choice therapy in arterial hypertension? *Minerva Med*. 2019;110(6):546–554. doi:[10.23736/S0026-4806.19.06282-7](https://doi.org/10.23736/S0026-4806.19.06282-7).
- [82] Bogomaz A, Kotovskaya Y, Kobalava Z. Combination with amlodipine eliminates adverse effect of a betablocker on aortic pulse pressure augmentation. *J Hypertens*. 2015;33(e-Suppl 1):e326. doi:[10.1097/01.hjh.0000468379.55561.95](https://doi.org/10.1097/01.hjh.0000468379.55561.95).
- [83] Kobalava ZD, Kotovskaya YV, Bogomaz AV. The fixed combination of amlodipine and bisoprolol eliminates the effect of β -blockers on central pulse wave in patients with arterial hypertension. *Kardiologiia*. 2015;55(12):11–16. doi:[10.18565/cardio.2015.12.11-16](https://doi.org/10.18565/cardio.2015.12.11-16).
- [84] Taddei S, Virdis A, Ghiadoni L, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. *Hypertension*. 2001;37(3):943–948. doi:[10.1161/01.hyp.37.3.943](https://doi.org/10.1161/01.hyp.37.3.943).
- [85] Pugliese NR, Masi S, Taddei S. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. *Heart Fail Rev*. 2020;25(1):31–42. doi:[10.1007/s10741-019-09855-5](https://doi.org/10.1007/s10741-019-09855-5).
- [86] Guo QH, Zhu ZM, Feng YQ, et al. Blood pressure lowering effects of β -blockers as add-on or combination therapy: a meta-analysis of randomized controlled trials. *J Clin Hypertens (Greenwich)*. 2023;25(3):227–237. doi:[10.1111/jch.14616](https://doi.org/10.1111/jch.14616).
- [87] Amatruda JG, Scherzer R, Rao VS, et al. Renin-angiotensin-aldosterone system activation and diuretic response in ambulatory patients with heart failure. *Kidney Med*. 2022;4(6):100465. doi:[10.1016/j.xkme.2022.100465](https://doi.org/10.1016/j.xkme.2022.100465).
- [88] Taddei S. Fixed-dose combination therapy in hypertension: pros. *High Blood Press Cardiovasc Prev*. 2012;19(2):55–57. doi:[10.1007/BF03262454](https://doi.org/10.1007/BF03262454).
- [89] Gottwald-Hostalek U, Sun N. Contribution of single-pill combinations in the management of hypertension: perspectives from China, Europe and the USA. *Curr Med Res Opin*. 2023;39(3):331–340. doi:[10.1080/03007995.2023.2165812](https://doi.org/10.1080/03007995.2023.2165812).
- [90] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42(36):3599–3726. doi:[10.1093/eurheartj/ehab368](https://doi.org/10.1093/eurheartj/ehab368).
- [91] Sevre K, Rist A, Wachtell K, et al. What is the current best drug treatment for hypertensive heart failure with preserved ejection fraction? review of the totality of evidence. *Am J Hypertens*. 2024;37(1):1–14. doi:[10.1093/ajh/hpad073](https://doi.org/10.1093/ajh/hpad073).
- [92] Verma S, Dhingra NK, Butler J, et al. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. *Lancet Diabetes Endocrinol*. 2022;10(1):35–45. doi:[10.1016/S2213-8587\(21\)00292-8](https://doi.org/10.1016/S2213-8587(21)00292-8).